Pipeline Resurrection: An Interview With Interleukin Genetics CEO Lewis Bender (Part 1)
This article was originally published in The Pink Sheet Daily
Executive Summary
Diagnostic technology could revive countless abandoned projects in Big Pharma R&D pipelines. But making that happen is harder than you think.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
“The Right Approach” To Regulating Biomarkers: An Interview With Interleukin Genetics CEO Lewis Bender (Part 3)
Setting standards in an emerging area of science is a big challenge, both for FDA and regulated industry. One diagnostics CEO thinks FDA is taking an appropriately careful approach.